ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Graff on the Role of Checkpoint Inhibitors in Prostate Cancer

Julie Graff, MD
Published: Tuesday, Dec 26, 2017



Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the role of checkpoint inhibitors and PARP inhibitors for patients with prostate cancer.

According to Graff, there is potential for CTLA-4, PD-1, and PD-L1 to move into prostate cancer. However, there are 2 negative studies of ipilimumab (Yervoy). Therefore, that may not move forward unless it is combined with another therapy or patients are molecularly tested and it is determined as an appropriate form of therapy. There are multiple studies looking at PD-1 therapies in combination.

Additionally, PARP inhibition for patients with tumors expressing DNA-repair defects is very promising, explains Graff. There is a trial out of the National Cancer Institute looking at the PARP inhibitor olaparib (Lynparza) with the PD-1 inhibitor durvalumab (Imfinzi) that is showing promising results.
 


Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the role of checkpoint inhibitors and PARP inhibitors for patients with prostate cancer.

According to Graff, there is potential for CTLA-4, PD-1, and PD-L1 to move into prostate cancer. However, there are 2 negative studies of ipilimumab (Yervoy). Therefore, that may not move forward unless it is combined with another therapy or patients are molecularly tested and it is determined as an appropriate form of therapy. There are multiple studies looking at PD-1 therapies in combination.

Additionally, PARP inhibition for patients with tumors expressing DNA-repair defects is very promising, explains Graff. There is a trial out of the National Cancer Institute looking at the PARP inhibitor olaparib (Lynparza) with the PD-1 inhibitor durvalumab (Imfinzi) that is showing promising results.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x